Technical Briefing on Experiences with Bioprospecting and Access & Benefit Sharing (ABS) Regulations
6 May 2010
13:30 to 14:45
World Intellectual Property Organization, Room B
This event has now passed. To browse our upcoming events click here.
Sustainable access to genetic material and mutually agreed distribution of any benefits are common goals shared by the biopharmaceutical industry, governments and civil society. In order to ensure an enabling environment for the creation of biopharmaceutical products, policymakers should endeavor to base national and international regulations on terms that are clear, workable in practice and take into account relevant current experiences. This IFPMA briefing is intended to improve understanding on this complex issue by highlighting experiences from a developing country SME perspective as well as from the wider pharmaceutical industry.
Welcome and introduction
to common trends in successful
Andrew Jenner, Director, Intellectual
Property and Trade, IFPMA, Geneva
EXTRACTA’s experience with
ABS regulations in Brazil
Prof. Antônio Carvalho, President
and CEO EXTRACTA Moléculas
Naturais S/A, Rio de Janeiro
Q & A
Andrew Jenner is Director of Innovation, Intellectual Property (IP) & Trade at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). He is responsible for developing pharmaceutical industry strategy on Intellectual Property policy and represents the industry on IP and trade related issues within the UN and the World Trade Organization. He also leads a team of policy experts on trade, biotherapeutics and influenza vaccines. From 2007 until 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy Group for the UK Intellectual Property Office (IPO), bringing together Government departments, Enforcement agencies and Industry to combat Intellectual Property Crime. From 2004 – 2007 he was Head of Trade & Development at the IPO and lead the IP discussions within the World Trade Organization (WTO), the World Health Organization (WHO) and World Intellectual Property Organization’s (WIPO) Intergovernmental Committee on genetic resources. He also led on policy relating to EU/UK IP pharmaceutical regulations, including negotiating the EU Regulation on the compulsory licensing of pharmaceutical products for export, and implementation of the EU ‘bolar exemption’ and Paediatric Medicines Regulation into UK law. He first joined the UK Government in 1998 as a patent examiner having previously worked in the automotive industry as a quality control advisor. He remains a member of the Institute of Engineering and Technology having a Bachelor degree in Engineering and a Master of Laws.